An Opportunity to Transform Health
Invest in groundbreaking biotech innovations that optimize longevity and healthspan, driving a healthier and more vibrant future.
The goal of longevity research is not only to extend lifespan but also to expand and optimize “Healthspan”.
Healthspan refers to the number of years a person lives in good health, free from chronic diseases and disabilities.
Zephyr Group, Inc (Zephyr)
Our mission is simple:
Optimize the healthy human healthspan through innovative biotechnology solutions.
The combination of advanced biotechnology innovations aligned with traditional remedies, adaptogenic herbs, essential bioactive compounds, and phytoceuticals, delivered via therapeutic wellness and lifestyle products, presents a myriad of greenfield investment and commercial opportunities.
FOCUS
Zephyr Well Positioned to Capitalize
- Patents for various product categories.
- Existing proprietary product compounds/formulations.
- Lead clinical asset for Type II Diabetes, Pain Management, Obesity, Skincare, and Mental health.
- Focus on “Precision Medicine”.
- Established cGMP Manufacturing.
- Domestic and International Joint Venture/Distribution Partners.
- University and Pharmaceutical Affiliations.
Innovative Approach to Health & Longevity: Zephyr’s proprietary peptide and phytoceutical solutions are being developed with the goal of addressing diabetes, obesity, and aging-related diseases through precision medicine.
Global Market
The biotech and nutraceutical industries are targeting some of the same lifestyle disease growth markets.
The Outlook – Market Size – Advancing Personalized Medicine
With the goal to optimize healthspan. We are developing innovative biotechnology solutions to tackle the challenges of Aging and improve the quality of life for individuals worldwide.
The Synergistic Power of Bioactive Compounds – A modern “plant-based” industrial revolution is emerging, the convergence of peptides and phytoceuticals represents a transformative shift in healthcare, wellness and sustainability.
INNOVATION
Utilizing emerging technologies ~ Advancing healthcare, Empowering lives.
BioTechnology
Biotechnology holds immense potential in extending healthspan and improving quality of life as we age.
- Research andBiomarkers
- Epigenetic Testing
- AI and New Drug Targets
- Pharmacological Interventions
- Nutrition and Supplements
Obesity and Diabetes
Diabetes is the leading cause of death in Mexico, killing nearly 80,000 people each year. In the US, diabetes is the sixth leading cause of death.
- Obesity is a worldwide epidemic caused by an increase in the consumption of foods with poor nutritional value
- The United States and Mexico have high rates of obesity and diabetes
- Our the diabetes product line could enhance Zephyr Group's market position and valuation.
FOCUS
At the forefront of our portfolio is a lead candidate addressing Type 2 diabetes that is demonstrating early clinical evidence of significant improvements in key health markers including blood glucose, hemoglobin A1c, cholesterol and triglycerides.
- Multinational (US and Mexico) protocol for clinical study submission of our patented natural type II diabetes compound
- Development of a new, effective, natural diabetes medication could have a profound impact on patients worldwide
- Significant improvements in key health markers, including blood glucose, hemoglobin A1c, cholesterol and triglycerides
- New molecular entities as well as novel drug delivery technologies, creating truly transformative treatments
- Development of the diabetes product line to enhance Zephyr Group's market position and valuation.
Trial Results: Graph shows average improvement in blood sugar and lipid values after 3 months of treatment